Astra + Zeneca (A): "Merger of equals"
Consolidations and paradigm shifts in the pharmaceutical industry in the 1990s induced Astra and Zeneca to review potential merger partners. Both companies were confident of surviving on their own, banking on organic growth. However, escalating costs in R&D and sales and marketing, patent expiries, benefits of scale, and pressure on prices made this increasingly difficult to sustain. After 6 months of discussion, Astra and Zeneca announced a “merger of equals” in December 1998. This first part of a two-part case series looks at some of the “black box issues,” how they were negotiated to ensure that this was indeed a merger of equals and the final outcome of the negotiations.
September 1998
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
- Astra + Zeneca (A): "Merger of equals"
- Astra + Zeneca (B): Forming a new company
- Astra + Zeneca (A): "Merger of equals"
- Astra + Zeneca (B): Forming a new company
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
To some, Apple is starting to look like a company on the back foot. The appointment of Mr John Ternus, a long-time hardware chief, to CEO only sharpens the question of whether the US$4 trillion (S$5 trillion) company can keep pace in artificial in...
Ask a roomful of executives whether their company takes sustainability seriously, and almost every hand goes up. But ask whether their sustainability investments are generating real commercial returns, and the room may get quieter. The gap between...
City Developments Limited (CDL), one of Singapore's largest listed property developers, had been a cornerstone of the Kwek family business empire in Singapore since 1972. With an enterprise value of S$19.5 billion (US$15.1 billion) in January 2026...
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD 14 April 2026
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD Brain Circuits 9 April 2026
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD Brain Circuits 11 March 2026
Research Information & Knowledge Hub for additional information on IMD publications